These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38521388)

  • 21. Apoptosis and non-alcoholic fatty liver diseases.
    Kanda T; Matsuoka S; Yamazaki M; Shibata T; Nirei K; Takahashi H; Kaneko T; Fujisawa M; Higuchi T; Nakamura H; Matsumoto N; Yamagami H; Ogawa M; Imazu H; Kuroda K; Moriyama M
    World J Gastroenterol; 2018 Jul; 24(25):2661-2672. PubMed ID: 29991872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of hepatic Flcn protects against fibrosis and inflammation by activating autophagy pathways.
    Paquette M; Yan M; Ramírez-Reyes JMJ; El-Houjeiri L; Biondini M; Dufour CR; Jeong H; Pacis A; Giguère V; Estall JL; Siegel PM; Audet-Walsh É; Pause A
    Sci Rep; 2021 Oct; 11(1):21268. PubMed ID: 34711912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells.
    Tan Y; Watkins AA; Freeman BB; Meyers JA; Rifkin IR; Lerner A
    J Immunol; 2015 Jan; 194(1):101-12. PubMed ID: 25416804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis.
    Wang Q; Zhou H; Bu Q; Wei S; Li L; Zhou J; Zhou S; Su W; Liu M; Liu Z; Wang M; Lu L
    J Hepatol; 2022 Aug; 77(2):312-325. PubMed ID: 35292349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of cellular FLICE-inhibitory protein promotes acute cholestatic liver injury and inflammation from bile duct ligation.
    Gehrke N; Nagel M; Straub BK; Wörns MA; Schuchmann M; Galle PR; Schattenberg JM
    Am J Physiol Gastrointest Liver Physiol; 2018 Mar; 314(3):G319-G333. PubMed ID: 29191940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A TNFα/Miz1-positive feedback loop inhibits mitophagy in hepatocytes and propagates non-alcoholic steatohepatitis.
    Jin K; Shi Y; Zhang H; Zhangyuan G; Wang F; Li S; Chen C; Zhang J; Wang H; Zhang W; Sun B
    J Hepatol; 2023 Aug; 79(2):403-416. PubMed ID: 37040844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FTZ attenuates liver steatosis and fibrosis in the minipigs with type 2 diabetes by regulating the AMPK signaling pathway.
    Wang H; Huang M; Bei W; Yang Y; Song L; Zhang D; Zhan W; Zhang Y; Chen X; Wang W; Wang L; Guo J
    Biomed Pharmacother; 2021 Jun; 138():111532. PubMed ID: 34311531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD).
    Subramanian P; Hampe J; Tacke F; Chavakis T
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805998
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of phosphodiesterase-4 in the spinal dorsal horn ameliorates neuropathic pain via cAMP-cytokine-Cx43 signaling in mice.
    Zhang FF; Wang H; Zhou YM; Yu HY; Zhang M; Du X; Wang D; Zhang F; Xu Y; Zhang JG; Zhang HT
    CNS Neurosci Ther; 2022 May; 28(5):749-760. PubMed ID: 35156776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucagon-like peptide 1 and fibroblast growth factor-21 in non-alcoholic steatohepatitis: An experimental to clinical perspective.
    Yadav P; Khurana A; Bhatti JS; Weiskirchen R; Navik U
    Pharmacol Res; 2022 Oct; 184():106426. PubMed ID: 36075510
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis.
    Pejnovic N; Jeftic I; Jovicic N; Arsenijevic N; Lukic ML
    World J Gastroenterol; 2016 Nov; 22(44):9706-9717. PubMed ID: 27956794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).
    Min-DeBartolo J; Schlerman F; Akare S; Wang J; McMahon J; Zhan Y; Syed J; He W; Zhang B; Martinez RV
    PLoS One; 2019; 14(12):e0226854. PubMed ID: 31891606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibiting Interleukin 11 Signaling Reduces Hepatocyte Death and Liver Fibrosis, Inflammation, and Steatosis in Mouse Models of Nonalcoholic Steatohepatitis.
    Widjaja AA; Singh BK; Adami E; Viswanathan S; Dong J; D'Agostino GA; Ng B; Lim WW; Tan J; Paleja BS; Tripathi M; Lim SY; Shekeran SG; Chothani SP; Rabes A; Sombetzki M; Bruinstroop E; Min LP; Sinha RA; Albani S; Yen PM; Schafer S; Cook SA
    Gastroenterology; 2019 Sep; 157(3):777-792.e14. PubMed ID: 31078624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perilipin-2 promotes obesity and progressive fatty liver disease in mice through mechanistically distinct hepatocyte and extra-hepatocyte actions.
    Orlicky DJ; Libby AE; Bales ES; McMahan RH; Monks J; La Rosa FG; McManaman JL
    J Physiol; 2019 Mar; 597(6):1565-1584. PubMed ID: 30536914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease.
    Brown E; Hydes T; Hamid A; Cuthbertson DJ
    Clin Ther; 2021 Sep; 43(9):1476-1504. PubMed ID: 34446271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis, and biological evaluation of tetrahydroisoquinolines derivatives as novel, selective PDE4 inhibitors for antipsoriasis treatment.
    Zhang R; Li H; Zhang X; Li J; Su H; Lu Q; Dong G; Dou H; Fan C; Gu Z; Mu Q; Tang W; Xu Y; Liu H
    Eur J Med Chem; 2021 Feb; 211():113004. PubMed ID: 33218684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis.
    Liu C; Schönke M; Spoorenberg B; Lambooij JM; van der Zande HJP; Zhou E; Tushuizen ME; Andreasson AC; Park A; Oldham S; Uhrbom M; Ahlstedt I; Ikeda Y; Wallenius K; Peng XR; Guigas B; Boon MR; Wang Y; Rensen PCN
    Elife; 2023 Jan; 12():. PubMed ID: 36648330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Baicalin attenuates non-alcoholic steatohepatitis by suppressing key regulators of lipid metabolism, inflammation and fibrosis in mice.
    Zhang J; Zhang H; Deng X; Zhang N; Liu B; Xin S; Li G; Xu K
    Life Sci; 2018 Jan; 192():46-54. PubMed ID: 29158052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Involvement of eNAMPT/TLR4 inflammatory signaling in progression of non-alcoholic fatty liver disease, steatohepatitis, and fibrosis.
    Sun BL; Sun X; Kempf CL; Song JH; Casanova NG; Camp SM; Reyes Hernon V; Fallon M; Bime C; Martin DR; Travelli C; Zhang DD; Garcia JGN
    FASEB J; 2023 Mar; 37(3):e22825. PubMed ID: 36809677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmaceutical Efficacy of Gypenoside LXXV on Non-Alcoholic Steatohepatitis (NASH).
    Lee JH; Oh JY; Kim SH; Oh IJ; Lee YH; Lee KW; Lee WH; Kim JH
    Biomolecules; 2020 Oct; 10(10):. PubMed ID: 33050067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.